Physicians' Academy for Cardiovascular Education

Triglycerides

Explained risk from apoB-containing lipoproteins to MI

5' education - Jan. 13, 2021 - Prof. Børge Nordestgaard, MD

Results of omega-3 fatty acids trials may not be contradictory

3' education - Nov. 16, 2020 - Prof. Deepak Bhatt, MD

No effect of omega-3 carboxylic acid on MACE in high-risk patients

3' education - Nov. 16, 2020 - Prof. Michael Lincoff, MD

Lessons from REDUCE-IT

10' education - Nov. 12, 2020 - Prof. Deepak Bhatt, MD - Online CME

Latest results with non-LDL lowering agents in reducing CV risk

10' education - Oct. 26, 2020 - Prof. Ulrich Laufs, MD

Non-LDL-c parameters in CV risk management and guidelines

10' education - Oct. 13, 2020 - Prof. Kausik Ray, MD - Online CME

Updates in the 2019 ESC/EAS guidelines for the management of dyslipidemia

10' education - Sep. 29, 2020 - Prof. François Mach, MD

The residual risk challenge in CVD: How important are triglycerides?

10' education - Sep. 25, 2020 - Prof. Ulf Landmesser, MD

A marriage of clinical trial results and imaging findings with icosapent ethyl

10' education - Sep. 21, 2020 - Fabrice Martens, MD, PhD, prof. Matthew Budoff, MD and prof. Gabriel Steg MD

Burden of residual risk: Are triglycerides a risk marker?

10' education - Aug. 18, 2020 - Prof. Klaus Parhofer, MD

Reduction of revascularization with icosapent ethyl in patients with hypertriglyceridemia

3' education - May 25, 2020 - Benjamin Peterson, MD

Mechanistic underpinning of CV benefit observed with icosapent ethyl

3' education - Apr. 2, 2020 - Prof. Deepak Bhatt, MD - ACC 2020

Lipids beyond LDL-c: HDL-c and triglycerides

5' education - Feb. 25, 2020 - Prof. Peter Libby, MD

Reducing triglycerides in REDUCE-IT

10' education - Feb. 11, 2020 - Prof. Deepak Bhatt, MD - Online CME

The spectrum of triglyceride-containing lipoproteins

10' education - Feb. 4, 2020 - Jorge Plutzky, MD - Online CME

How can triglycerides increase CV risk?

10' education - Jan. 16, 2020 - Prof. Børge Nordestgaard, MD

The burden of residual CV risk in the statin era

5' education - Jan. 6, 2020 - Erin Bohula, MD

Three lines of evidence for triglycerides as a CV risk factor

10' education - Dec. 17, 2019 - Prof. Ph. Gabriel Steg

Possible favorable effects of icosapent ethyl on plaque-parameters

3' education - Nov. 25, 2019 - Prof. Stephen Nicholls - AHA 2019, Philadelphia

Unexpectedly large CV benefit with icosapent ethyl in statin-treated patients at high CV risk

3' education - Nov. 20, 2018 - Prof. Erik Stroes, MD

Highly purified EPA reduces important ischemic events in hypertriglyceridemia

3' education - Nov. 11, 2018 - Deepak Bhatt, MD - Boston, MA, USA.
##SCROLLER_ITEMS_FULL_TITLE##

New, more potent chemical agent to lower triglyceride levels

3' education - May 24, 2015 - ISA2015, Amsterdam - Harold Bays
##SCROLLER_ITEMS_FULL_TITLE##

Increase in LDL may not always be associated with increase in CV risk

3' education - May 25, 2015 - ISA Amsterdam, May 25, 2015 - Allyson Morton
##SCROLLER_ITEMS_FULL_TITLE##

2014: the major lipid developments in review

3' education - Dec. 20, 2014 - Amsterdam - Prof. John JP Kastelein
##SCROLLER_ITEMS_FULL_TITLE##

Hypertriglyceridemia: New small-molecule based strategies

10' education - Oct. 1, 2014 - Barcelona - Christie Ballantyne MD
##SCROLLER_ITEMS_FULL_TITLE##

Targeting fasting and post-prandial triglycerides

3' education - Sep. 1, 2013 - Snapshot 2013 - Dr. Joanne M. Donovan
##SCROLLER_ITEMS_FULL_TITLE##

Targeting triglycerides: New insights from antisense therapy

10' education - Sep. 14, 2013

ESC debate | Do patients benefit from omega-3 fatty acids?

News - Sep. 7, 2021
Two recent trials with fish oil, the REDUCE-IT trial and the STRENGTH trial, have shown conflicting results. How should we interpret these findings? Several lipid experts go through the evidence and provide their views.

ESC 2021 Two recent trials with fish oil, the REDUCE-IT trial and the STRENGTH trial, have shown conflicting results. How should we interpret these findings? Several lipid experts go through the evidence and provide their views.

Consensus recommendations for ASCVD risk reduction in hypertriglyceridemia

News - Aug. 10, 2021

The ACC has published an Expert Consensus Decision Pathway which provides practical recommendations on lifestyle modifications in patients with hypertriglyceridemia and use of statins and TG risk-based non-statin therapies for ASCVD risk reduction.

Omega-3 fatty acids supplementation associated with increased risk of incident AF

Literature - June 15, 2021 - Lombardi M et al. - Eur Heart J Cardiovasc Pharmacother. 2021

This meta-analysis of five RCTs (REDUCE-IT, ASCEND, R&P, STRENGTH and OMEMI) showed that omega-3 fatty acids supplementation is associated with an increased risk of incident AF, compared to placebo.

Icosapent ethyl reduces whole-heart coronary atherosclerotic plaque burden

News - May 31, 2021

ACC 2021 This subanalysis of the EVAPORATE trial showed a significant reduction in whole-heart atherosclerotic plaque burden over 18 months in statin-treated patients with elevated triglyceride levels who received icosapent ethyl compared to those on placebo.

TG reduction with ANGPTL3 antibody in patients with severe hypertriglyceridemia

News - May 19, 2021

ACC 2021 A phase 2 study showed that evinacumab resulted in reduction of TGs in patients with severe hypertriglyceridemia, but lowering was variable and dependent on genotype.

ApoB and non-HDL-c are better markers of residual risk than LDL-c in statin-treated patients

Literature - Apr. 7, 2021 - Johannesen CDL et al. - J Am Coll Cardiol. 2021

Elevated levels of apoB and non-HDL-c better reflect residual risk for all-cause mortality and MI than LDL-c levels in patients treated with statins.

European Commission approval for icosapent ethyl to reduce CV risk

News - Mar. 30, 2021

Icosapent ethyl has received EC approval to reduce CV risk in high-risk statin-treated patients who have elevated triglycerides and either established CVD or diabetes and ≥1 additional CV risk factor.

Icosapent ethyl recommended for EU approval by CHMP to reduce CV risk

News - Feb. 2, 2021

Following the results from the REDUCE-IT trial, the CHMP of the EMA has issued a positive recommendation for icosapent ethyl to reduce CV events in patients with established CVD or with diabetes and an additional risk factor.

Explained risk from apoB-containing lipoproteins to MI

5' education - Jan. 13, 2021 - Prof. Børge Nordestgaard, MD
A study using data from the Copenhagen General Population Study showed that cholesterol in VLDL explains 50% of the MI risk from apoB-containing lipoproteins. Triglycerides in VLDL explain 0%.

A study using data from the Copenhagen General Population Study showed that cholesterol in VLDL explains 50% of the MI risk from apoB-containing lipoproteins. Triglycerides in VLDL explain 0%. With poll.

VLDL cholesterol explains half of MI risk from apoB-containing lipoproteins

Literature - Jan. 5, 2021 - Balling M, et al. - J Am Coll Cardiol 2020

In a prospective study using data from the Copenhagen General Population Study, VLDL cholesterol explained 50% of risk in the association between apoB-containing lipoproteins and MI, whereas VLDL triglycerides did not contribute to this risk.

E-learning The evolving role of triglyceride-rich lipoproteins

EBAC-accredited E-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

This educational program consists of three presentations on residual CVD risk with a focus on triglycerides and triglyceride-rich lipoproteins.

Remnant-c and TG associated with MACE in high CV risk overweight or obese subjects

Literature - Dec. 15, 2020 - Castañer O, et al. - J Am Coll Cardiol. 2020

Triglycerides and remnant-c, but not LDL-c and HDL-c, were associated with MACE in a primary prevention cohort of high CV risk subjects with high prevalence of diabetes and obesity.